A phase 1 pharmacokinetic and pharmacodynamic trial comparing extended release (XR) of Ralinepag to the immediate release (IR) formulation of Ralinepag in healthy volunteers

Trial Profile

A phase 1 pharmacokinetic and pharmacodynamic trial comparing extended release (XR) of Ralinepag to the immediate release (IR) formulation of Ralinepag in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ralinepag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 29 Jun 2017 Status changed from recruiting to completed, according to an Arena Pharmaceuticals media release.
    • 29 Jun 2017 Results published in an Arena Pharmaceuticals media release.
    • 22 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top